US Pharma MarketingThe large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.
Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point
<figure><div><img src="https://imgproxy.divecdn.com/mCCaCIMMIxMEmMvKlor5tsxNXxsNwIl-ktBv8TKVzpc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjQ5Nzk3MjAzLmpwZWc=.webp"/></div></figure><p>The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.</p>
Source: PharmaVoice